The reclassification of cannabis to Schedule III could inject $3.5 billion into the sector, driving down costs and boosting activity. Undervalued pot stocks may benefit from regulatory improvements under the new administration. Quest Diagnostics could profit from increased marijuana testing demand and its strong position in the industry.